ArticleThe American Journal of dermatopathology2025
Histopathologic and Clinical Characteristics of Cutaneous Toxicities of Tyrosine Kinase Inhibitors: Insights Into Pathologic Mechanisms From a Retrospective Cohort.
Article in The American Journal of dermatopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDermatologic adverse events (dAEs) are prevalent with BCR-ABL tyrosine kinase inhibitors (TKIs), affecting quality of life and treatment adherence. Despite their prevalence, underlying mechanisms of toxicity remain unclear. We sought to characterize dAEs across TKI generations to elucidate mechanisms driving toxicities.
methodsRetrospective cohort study of patients receiving imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib at Memorial Sloan Kettering Cancer Center between 2001 and 2023 with dermatologic biopsy for TKI-related dAEs. Clinical and histopathologic characteristics were analyzed. Fisher exact test, with Freeman-Halton extension, was used to determine statistically significant differences.
resultsAmong 28 patients with 32 unique dAEs, imatinib was implicated in 32.1% of patients, second-generation TKIs in 57.1%, and ponatinib in 10.7%. Imatinib-induced dAEs exhibited significantly higher rates of papular/plaque morphology ( P = 0.02) with acanthosis ( P = 0.001) and eosinophilic infiltrates ( P = 0.02). Second-generation TKIs frequently caused folliculocentric eruptions with adnexal involvement. Ponatinib-related dAEs demonstrated significantly higher rates of ichthyosiform ( P = 0.002) and pityriasiform ( P = 0.02) morphologies with hyperkeratosis and fibrosis. No biopsy-confirmed asciminib dAEs were available.
conclusionsdAE pathogenesis varies across TKI generations, suggesting distinct patterns of inflammation and keratinocyte dysregulation. Imatinib-related dAEs demonstrated epidermal hyperplasia and eosinophilic inflammation, suggesting immune-mediated hypersensitivity as an important mechanism of toxicity. Second-generation TKI dAEs demonstrated prominent adnexal and perivascular involvement, possibly driven by off-target inhibition and proinflammatory mechanisms. Ponatinib dAEs reflected chronic epidermal alterations, possibly driven by off-target vascular endothelial growth factor receptor, fibroblast growth factor receptor, and Src-family kinase inhibition. Limited sample size, particularly for third-generation TKIs, limits generalizability. Understanding these differences may improve management strategies, optimizing patient quality of life and treatment continuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.